Net Loss Per Share |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Loss Per Share | 12. Net Loss Per Share Basic and diluted earnings per share are calculated as follows:
Stock options for the purchase of 22,842,960 shares of common stock, 2,247,064 restricted stock units, 2,465,985 performance-based restricted stock units and 24,363 ESPP shares were excluded from the computation of the net loss per share for the year ended December 31, 2025, due to the net loss during the period as their effect is antidilutive.
Stock options for the purchase of 20,166,069 shares of common stock, 2,523,052 restricted stock units, 1,782,870 performance-based restricted stock units and 30,062 ESPP shares were excluded from the computation of the net loss per share for the year ended December 31, 2024, due to the net loss during the period as their effect is antidilutive. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||